Kornimate/medical-research-clean huggingface dataset:
the relationship between functional exercise capacity, respiratory muscle strength, trunk control, balance and activities of daily living in individuals with cerebral palsi

Conditions: Cerebral Palsy, Spastic

Summary: cerebral palsy (cp) causes problems in posture, movement, breathing, postural control and balance in individuals. this work; this study was conducted to examine the relationship between functional exercise capacity, respiratory muscle strength, trunk control, balance and activities of daily living in individuals with spastic cerebral palsy.

cerebral palsy (cp) causes problems in posture, movement, breathing, postural control and balance in individuals. this work; this study was conducted to examine the relationship between functional exercise capacity, respiratory muscle strength, trunk control, balance and activities of daily living in individuals with spastic cerebral palsy. 23 children with spastic type cp and 22 typically developing children aged 6-18 years were included in the study. after recording the demographic data, the trunk control "trunk control measurement scale" (tcms), the activities of daily living "pediatric disability assessment inventory" (pdi), the balance "pediatric berg balance scale" (pbdi), functional exercise capacity "2 minute walking test" and respiratory muscle strength was evaluated with maximum inspiratory pressure (mip) and maximum expiratory pressure (mep) measurements. compared to individuals with typical development, individuals with cp had lower tcms, ppi, pbrs, 2-minute walking test and respiratory muscle strength values (p\<0.01). at the same time, it was observed that individuals with hemiparetic cp had better tcms, ppi, pbrs scores, functional exercise capacities and respiratory muscle strength compared to individuals with diparetic disease and individuals with cp at gmfcs i level compared to individuals with other levels. it was found that there was a high correlation between trunk control, balance and functional capacity of individuals with cp. it was concluded that the influence on trunk control affects balance and functional capacity. there was also a correlation between the scales.

Eligibility criteria:
inclusion criteria: * being between 6-18 years old, * having been diagnosed with spastic hemiplegic or spastic diplegic cerebral palsy, * no communication problem, * gmfcs level was determined to be between i-iii. exclusion criteria: * the parent who will answer the form does not know turkish, * orthopedic surgical treatment and botulinum toxin injection in the 6 months before the study, * it was determined as having other orthopedic, neurological and cardiopulmonary diseases that may affect balance and gait.

Keywords: trunk control respiratory muscle strength balance
pregabalin for alcohol dependence

Conditions: Alcoholism

Summary: the study hypothesis is: pregabalin is superior to placebo in preventing relapse to drinking and reducing drinking severity

this is a two cell double blind placebo controlled randomized clinical trial of pregabalin for alcohol dependence

Eligibility criteria:
inclusion criteria: * alcohol dependence by icd-x criteria exclusion criteria: * severe co-morbid psychiatric and somatic diseases

Keywords: pregabalin patients treatment
effect of ageing on airway remodeling

Conditions: Aging

Summary: the aim of the study is to investigate the relationship between aging and morphological changes in the lung. 120 consecutive healthy volunteers over 60 years will be enrolled for this trial.

chest multidetector ct without injection and spirometry data will be obtained from a multicentric sample of individuals between 60 and 95 years of ageexclusion criteria were current smoking, history of smoking within the past 10 years, any known chronic or acute pulmonary disease. individuals treated with amiodarone, bleomycin or methotrexate were excludedoutcome

Eligibility criteria:
inclusion criteria: * people from 60 to 95 years old free from chest disease or history of chest disease exclusion criteria: * chronic cough * dyspnea * sinonasal or chest infection during enrollment * myocardial infarction. * current smoker or past smoker with more than 10 pack year intoxication

Keywords: aging lung airway remodeling airway segmentation chest ct
open vs laparoscopic liver surgery for colorectal liver metastases

Conditions: Colorectal Liver Metastasis; Laparoscopic Liver Resection

Summary: this study evaluates the feasibility of laparoscopic surgery in patients diagnosed with colorectal liver metastases. half of participants will be operated on by laparoscopic approach and the results obtained will be compared with the results from the other half of patients operated on by open approach.

the safety and efficacy of liver surgery in the treatment of colorectal liver metastases are well established for the open approach. it allows good results in terms of complications, disease free survival and overall survival, and for these reasons it has become the gold standard technique in the treatment of colorectal liver metastases. on the contrary, the role of laparoscopic liver resection in this context is not so clear nowadays. generally, laparoscopic surgery offers some advantages such as less pain, shorter hospital stay and better aesthetic results. but the use of laparoscopic approach in liver surgery is still discussing: two international consensus conferences have been held and no strong conclusions have been made. furthermore for colorectal liver metastases no randomized trials, comparing both techniques, have been published until now. to assess the feasibility of laparoscopic liver resection for colorectal metastases, the investigators propose this trial in which the patients suitable for laparoscopic approach are randomized to open or laparoscopic group

Eligibility criteria:
inclusion criteria: * patients with colorectal liver metastases; * patients suitable for surgical treatment; * patients eligible for laparoscopy approach. exclusion criteria: * patients with high tumour load: multiples and bilobar colorectal metastases; * patients with big liver metastases or close to major vessels; * patients with oncological contraindications for surgery; * cirrhotic liver * needing for two stage liver resection; * medical or psychiatric condition of the patient that compromises the informed consent authorization; * refusal to participate in the study
comparison of effectiveness of disinfectants

Conditions: Root Canal Infection

Summary: this is a comparative experimental study to compare the efficacy of chemical disinfection agents , sodium hypochlorite and chlorhexidine gluconate in decontaminating gutta percha cones

the study design is a comparative study which was done to compare the efficacy of chemical disinfection agents on decontaminating the gutta percha cones . in this study, 124 standardized size-80 gutta-percha (gp) cones (dentsply, germany) were used to assess the efficacy of chemical disinfectants. the cones were first sterilized using ethylene oxide to ensure baseline sterility. following sterilization, 124 cones were allocated into two experimental groups (n = 62 each) for contamination. group a . gp were immersed in 20ml of enterococcus faecalis solution group b . gp were immersed in 20 ml of human saliva in patients undergoing root canal therapy samples were incubated at 37°c for 72 hours to ensure uniform and thorough contamination after incubation period cones were dried and divide into subgroups based on disinfectant agent applied . the cones were immersed in disinfectant agent for 1 min and 10 min . cones were dried again and immersed in brain heard infusion broth samples were again incubated at 37°c for 72 hours the presence of bacterial growth was determined by assessing turbidity in the broth, indicating viable microorganisms.

Eligibility criteria:
inclusion criteria: * healthy individual age between 20-40 patient needed root canal therapy exclusion criteria: * patient not willing to participate in study participants with systemic disease patients with neuromuscular disorder

Keywords: chemical disinfection chlorhexidine gluconate gutta percha sodium hypochlorite
a study of the feasibility of prehospital remote ischemic conditioning

Conditions: Chest Pain

Summary: prospective, single center, single arm pilot study evaluating the feasibility of delivering remote ischemic conditioning (ric) by emergency medical services (ems) in the prehospital setting. eligible patients will have chest pain or anginal equivalent symptoms and require ground ambulance transport to the hospital. all subjects will undergo the standard ric procedure (i.e., up to four cycles of alternating 5-min inflation and 5-min deflation) with the autoric® device (cellaegis devices, inc., toronto, ontario). the primary objective is to evaluate the number of cycles of ric completed in patients having the procedure initiated by ems in the prehospital setting.

this single-arm, open-label pilot study will evaluate the feasibility of delivering remote ischemic conditioning (ric) by emergency medical services (ems) in the prehospital setting. eligible patients will be at least 18 years of age, and require ground ambulance transport to the hospital. patients suspected of st-elevation myocardial infarction (stemi) based on the prehospital electrocardiogram and thus requiring urgent intervention in the cardiac catheterization lab will be excluded. all subjects will undergo the standard ric procedure (i.e., up to four cycles of alternating 5-min inflation and 5-min deflation) with the autoric® device (cellaegis devices, inc.). the automated procedure will be initiated by paramedics during ambulance transport, and the ric cycles will continue through emergency department (ed) arrival and stay for a total of 40 minutes. the primary objective of this pilot study is to examine the duration of ric administered in patients having the procedure initiated in the prehospital setting. the investigators hypothesize four cycles of ric will be completed in at least 80% of patients having the procedure initiated. secondary objectives are to assess enrollment rates and protocol implementation; paramedic acceptability of protocol; and patient tolerability of ric.

Eligibility criteria:
inclusion criteria: 1. requiring 9-1-1 response to scene 2. at least 18 years of age 3. experiencing non-traumatic chest pain or anginal equivalent symptom 4. not meeting ems criteria for a suspected stemi based on prehospital ecg 5. systolic blood pressure (sbp) between 100-180 mgm hg 6. designated for ambulance transport to university of north carolina medical center (chapel hill, nc) 7. capable of providing informed consent exclusion criteria: 1. unconscious or otherwise in critical condition 2. lacking capacity to consent to the study 3. non-english speaking 4. pre-existing condition precluding blood pressure check or use of the autoric® at the discretion of the provider or listed here: 1. paresis of upper limb 2. pre-existing traumatic injury to arm 3. presence of an arteriovenous shunt for dialysis 4. prior mastectomy 5. existing peripheral inserted central catheter line 6. arm edema or other indication of upper extremity thrombosis 5. serial ecg evidence of evolving stemi

Keywords: emergency medical services
rasburicase as a uricolytic therapy for hyperuricemia in patients with leukemia or lymphoma

Conditions: Hyperuricemia; Leukemia; Lymphoma

Summary: the primary objectives of the study are to evaluate the safety and the efficacy in patients with malignant lymphoma or acute leukemia who are repeatedly administered for sr29142 5 days in two dosage groups. secondary objectives are to determine the pharmacokinetic (pk) parameters of sr29142 , to assess anti-sr29142 antibody production in patients with malignant lymphoma and acute leukemia, and to estimate the optimal dosage of sr29142 for japanese patients from the results of efficacy and safety evaluations.


Eligibility criteria:
inclusion criteria: patient suffering from: * acute leukemia with white blood cell (wbc) count≥ 20,000/mm3 without regard to uric acid level ; or * lymphoma,stage ≥ iii without regard to uric acid level; or * lymphomas, stage ii with bulky disease; or * lymphoma or leukemia, without regard to classification or morphology, with uric acid level ≥ 8.0 mg/dl, and lactate dehydrogenase (ldh) level ≥ twice the upper limit of normal (uln).
is sheep ghee cardioprotective?

Conditions: Cholesterol; Metabolic Disorder; Inflammation

Summary: normal volunteers were randomly received sheep ghee or sunflower oil, and before and after the study lipid profile and hs-crp were measured.

during outpatient clinic visits, potentially eligible individuals were screened for enrollment according to the inclusion and exclusion criteria. patients were randomly allocated into the treatment and control groups via the blocked randomization method. the control group received a normal diet for eight weeks with 10 g of sunflower oil. in the treatment group, sunflower oil was replaced with 10 g of sheep ghee. 50 patients in each group were enrollment. patients' information, including demographic data and the serum levels of fasting blood sugar (fbs), ldl, hdl, triglyceride (tg), and hs-crp, were recorded in datasheets twice: once before treatment with sheep ghee and once eight weeks later.

Eligibility criteria:
inclusion criteria: * healthy adults, seeking outpatient visit at professor kojuri cardiology clinic exclusion criteria: * any history of ischemic heart disease (ihd), * coronary artery bypass grafting (cabg) * percutaneous intervention (pci) * stroke * peripheral vascular diseases * use of anti-hyperlipidemic agents * unwillingness to participate. * need of tight hyperlipidemia control.

Keywords: atherosclerosis cardiovascular disease high-sensitivity c-reactive protein inflammation sheep ghee
brain effect mechanism of lever positioning manipulation on ldh analgesia based on multimodal mri

Conditions: Lumbar Disc Herniation; Multimodal Brain Function; Analgesia Mechanism; Lever Positioning Manipulation

Summary: in order to further investigate the key brain targets and central response mechanism characteristics of analgesia, the dominant disease of ldh was taken as the object of this study, which was divided into operation group, comfort group and healthy subjects group. firstly, dti probabilistic tracking method was used to detect the changes of the brain white matter in each group. then, the low-frequency amplitude (mfalff) and local consistency (reho) of each group were compared by fmri scanning imaging technology, and the features of local brain functional connectivity (fc) of pain matrix related brain regions as seed points were analyzed. finally, mrs technique was used to detect the brain signals of related metabolites glutamic acid (glu) and 1-aminobutyric acid (gaba), so as to elucidate the network regulation of lever-positioning operation on the analgesic brain effect of ldh and the biochemical mechanism of central nervous system. this multimodal mri technique provides biological basis for the clinical application of lever localization in ldh.


Eligibility criteria:
inclusion criteria: 1. patients suffering from low back pain and/or radicular leg pain; 2. persistent pain for at least six months that was nonresponsive to conservative treatments; 3. at least one epidural or facet joint corticosteroid injection in the last past year without pain relief or with an improvement in pain of less than two months. 4. lumbar protrusion level discopathy on mri corresponding to the level of pain. 5. no interventional pain treatment was applied within the last three months and patients needed a pain score equal or greater than four on the visual analogic scale (vas). - exclusion criteria: 1.patients with motor deficits, systemic infection, coagulation disorders, pregnancy； 2.vas pain score lower than four； 3.patients with any other condition that prevents an mri scan from being performed. -
neurokinin (nk) 1 antagonist for pathological aggression for harmful, impulsive, and self-/aggressive behaviour

Conditions: Aggression

Summary: neurokinin (nk) -1 antagonist will be administered to study patients in a double-blind placebo trial. patients receive assessments including anger disorder scale (ads) and modified overt aggression scale (moas) and perform computerized study tasks during mri before the trial begins. patients receive either one week of the drug or one week of placebo and perform the same tasks and assessments. then patients receive another week of the alternate pill, followed by another round of tasks during mri and assessments.


Eligibility criteria:
inclusion criteria: * are outpatients between 18 and 65 years old inclusive * meet diagnostic criteria for either intermittent explosive disorder or the adult-modified criteria for disruptive mood dysregulation disorder (appendix a) * have maintained a stable regimen of psychotropic medications (antidepressants, antipsychotics, anticonvulsants, and anxiolytics) for at least 4 weeks prior to study enrolment and throughout the duration of the treatment phase of the study * if participating in psychotherapy, must have been in stable treatment for at least 3 months prior to entry into the study, with no anticipation of change in the frequency of therapeutic sessions, or the therapeutic focus over the duration of the study * have capacity with respect to medical decision-making and consent to participate * pass the tms assessment safety survey (tass) mri safety questionnaire exclusion criteria: * have a diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or other primary psychotic disorder * meet criteria for a current manic episode or hypomanic episode * have a diagnosis of dementia or other neurodegenerative illness affecting the central nervous system * have a history of substance dependence or abuse within the last 3 months * are pregnant or currently nursing\* * \*patients will be tested before and after the study with a urine pregnancy test. * are taking contraindicated or interacting medications from product monograph of aprepitant * have an implanted intracranial device or pacemaker * have a diagnosis of severe hepatic insufficiency
study of effectiveness of gemdox in relapsed osteosarcoma

Conditions: Osteosarcoma Recurrent; Osteosarcoma Metastatic

Summary: a retrospective observational study of the effectiveness of gemcitabine - docetaxel in patients with relapsed osteosarcoma who have been treated with hd ifo in first line treatment


Eligibility criteria:
inclusion criteria: * age at diagnosis of high grade osteosarcoma \>= 4 * received first line treatment with hd ifo * following hd ifo treatment, they have been diagnosed refractory disease and they satisfy at least one of the following criteria : 1. relapsed in the first 24 month following the initial diagnosis, regardless of location and resectability 2. lung relapsed disease with more than 2 nodules diagnosed over 24 months from the initial diagnosis 3. non resectable relapsed disease diagnosed over 24 months from the initial diagnosis before or during gemdox treatment, eligible patients may have been subject to metastasectomy exclusion criteria: none
study of ruxolitinib in pancreatic cancer patients (janus 1)

Conditions: Pancreatic Cancer

Summary: determining the efficacy, based upon overall survival, of ruxolitinib added to capecitabine for the treatment of advanced or metastatic pancreatic cancer.

this was a randomized, double-blinded, placebo-controlled, phase 3 study, in which approximately 310 participants with advanced or metastatic adenocarcinoma of the pancreas who have failed, or were intolerant to first-line chemotherapy, were to be randomized (1:1) to one of the following treatment groups: * treatment a (n = 155): capecitabine + ruxolitinib * treatment b (n = 155): capecitabine + placebo treatment consisted of repeating 21-day cycles. capecitabine was self-administered for the first 14 days of each cycle, and ruxolitinib/placebo was self-administered daily for each cycle. treatment for all participants continued as long as the regimen was tolerated, and the participant did not meet discontinuation criteria. participants who discontinued study treatment before study termination were monitored for safety up to 30-35 days from the end of treatment. all participants were followed for survival until study termination or the safety follow-up visit.

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed adenocarcinoma of the pancreas. * advanced adenocarcinoma of the pancreas that is inoperable or metastatic. * eastern cooperative oncology group (ecog) performance status 0 to 2 * received 1 prior chemotherapy regimen for advanced or metastatic disease (not including neoadjuvant and/or adjuvant therapy). * ≥ 2 weeks elapsed from the completion of previous treatment regimen and participants must have recovered or be at a new stable baseline from any related toxicities. * radiographically measurable or evaluable disease * modified glasgow prognostic score (mgps) of 1 or 2 as defined below: 1. mgps of 1: c-reactive protein \>10 mg/l and albumin ≥35 g/l 2. mgps of 2: c-reactive protein \>10 mg/l and albumin \<35 g/l exclusion criteria: * received more than 1 prior regimen for advanced or metastatic disease. * ongoing radiation therapy, radiation therapy administered within 30 days of enrollment. * concurrent anticancer therapy (eg, chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, hormonal therapy, investigational therapy, or tumor embolization). * prior severe reaction to fluoropyrimidines, known dihydropyrimidine dehydrogenase deficiency (dpd), or other known hypersensitivity to active substances, including fluorouracil (5-fu), or ruxolitinib, or any of their excipients. * prior treatment with a jak inhibitor for any indication.

Keywords: metastatic pancreatic cancer metastatic pancreatic adenocarcinoma that is recurrent
virtual reality training program for ambulatory patients with chronic gait deficits after stroke

Conditions: Stroke

Summary: the purpose of this study is to examine the feasibility and efficacy of a virtual reality program for ambulatory patients with mild-to-moderate chronic gait deficits after stroke.

virtual reality (vr) systems enable the learning of simple and complex skills in a controlled virtual environment; i.e., one in which the different components (constraints) of the environment can be displayed, graded, changed and monitored in a quantitative manner. small preliminary studies suggest that vr may be used to augment chronic stroke rehabilitation and may enhance cortical reorganization. our aim is to examine the feasibility and efficacy of a virtual reality program for ambulatory patients with mild-to-moderate chronic gait deficits after stroke. study design-a single center randomized controlled trial of an experimental group and a usual care group.

Eligibility criteria:
main inclusion criteria: * stroke within 3-72 months. * mild-to-moderate residual gait deficits after the index stroke with preserved capacity for ambulation without or with an assistive device (e.g., walker, cane) or orthotics (e.g. afo). main exclusion criteria: * unstable cardiac or other medical condition or aphasia, dementia or other significant neurological disease limiting ability to train.

Keywords: stroke chronic gait deficits virtual reality training